Association of metallothionein expression and lack of apoptosis with progression of carcinogenesis in Barrett's esophagus

Experimental Biology and Medicine

Volumn 228, Issue 3, 2003, Pages 286-292

  Li, Yan ^a   Wo, John M ^a   Cai, Lu ^a   Zhou, Zhanxiang ^a   Rosenbaum, David ^a   Mendez, Christian ^a   Ray, Mukunda B ^a   Jones, Whitney F ^b   Kang, Y James ^a,b  

^a University of Louisville School of Medicine   (United States)

^b JEWISH HOSPITAL   (United States)

Author keywords

Apoptosis; Barrett's esophagus; Carcinogenesis; Metallothionein

Indexed keywords

METALLOTHIONEIN;

ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DYSPLASIA; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MALE; NICK END LABELING; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR BIOPSY;

EID: 0037340111     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020322800307     Document Type: Article

References (39)

1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265: 1287-1289, 1991.
2. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104:510-513, 1993.
3. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow cytometric and histologic progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort. Gastroenterology 102:1212-1219, 1992.
4. Hameeteman W, Tytgat GNJ, Houthoff HJ, Van Den Tweel JG. Barrett's esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology 96:1249-1256, 1989.
5. Cameron AJ. Barrett's esophagus: Dose the incidence of adenocarcinoma matter? Am J Gastroenterol 92:193-194, 1997.
6. Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, Kerr D, Young LS. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 154:965-973, 1999.
7. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 21:485-495, 2000.
8. Katada N, Hinder RA, Smyrk TC, Hirabayashi N, Perdikis G, Lund RJ, Woodward T, Klingler PJ. Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Arch Surg 132: 728-733, 1997.
9. Whittles CE, Biddlestone LR, Burton A, Barr H, Jankowski JA, Warner PJ, Shepherd NA. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: A comparative study. J Pathol 187:535-540, 1999.
10. Wetscher GJ, Schwelberger H, Unger A, Offner FA, Profanter C, Glaser K, Klingler A, Gadenstaetter M, Klinger P. Reflux-induced apoptosis of the esophageal mucosa is inhibited in Barrett's epithelium. Am J Surg 176:569-573, 1998.
11. Goldblum JR, Rice TW. bcl-2 protein expression in the Barrett's metaplasia-dysplasia-carcinoma sequence. Mod Pathol 8:866-869, 1995.
12. Coppola D, Schreiber RH, Mora L, Dalton W, Karl RC. Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma. Ann Surg Oncal 6:298-304, 1999.
13. Kang YJ. The antioxidant function of metallothionein in the heart. Proc Soc Exp Biol Med 222:263-273, 1999.
14. Jasani B, Schmid KW. Significance of metallothoinein overexpression in human tumors. Histopathology 31:211-214, 1999.
15. Oyama T, Takei H, Hikino T, Lino Y, Nakajima T. Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferation activity, histology and prognosis. Oncology 53:112-117, 1996.
16. Zelger B, Hittmair A, Schir M, Ofner C, Ofner D, Fritsch PO, Bocker W, Jasani B, Schmid KW. Immunohistochemically demonstrated metallothionein expression in malignant melanoma. Histopathology 23:257-264, 1993.
17. Ohshio G, Imamura T, Okada N, Wang ZH, Yamaki K, Kyogoku T, Suwa H, Yamabe H, Imamura M. Immunohistochemical study of metallothionein in pancreatic carcinomas. J Cancer Res Clin 122:351-355, 1996.
18. Hishikawa Y, Koji T, Dhar DK, Kinugasa S, Yamaguchi M, Nagasue N. Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br J Cancer 81:712-720, 1999.
19. Sampliner SE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus: the Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 93:1028-1032, 1998.
20. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H, MacDonald W, Owen D. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 19:166-178, 1988.
21. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25:982-993, 1994.
22. Cai L, Satoh M, Tohyama C, Cherian MG. Metallothionein in radiation exposure: its induction and protective role. Toxicology 132: 85-93, 1999.
23. Dietrich JB. Apoptosis and anti-apoptosis genes in the Bcl-2 family. Arch Physiol Biochem 105:125-135, 1997.
24. Bennett MR. Mechanisms of p53-induced apoptosis. Biochem Pharmacol 58:1089-1095, 1999.
25. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 33:29-55, 1999.
26. Cherian MG, Howell SB, Imura N, Klaassen CD. Role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol 126:1-5, 1994.
27. Helal T, Nassiri M, Khalifa A. Immunohistochemical markers of tumor prognosis in breast cancer in Egypt. Cancer Detect Prev 21:201-206, 1997.
28. Cohen JJ. Apoptosis: Mechanisms of life and death in the immune system. J Allergy Clin Immunol 103:548-554, 1999.
29. Eneman JD, Potts RJ, Osier M, Shukla GS, Lee CH, Chiu JF, Hart BA. Suppressed oxidant-induced apoptosis in cadmium adapted alveolar epithelial cells and its potential involvement in cadmium carcinogenesis. Toxicology 147:215-228, 2000.
30. Wetscher GJ, Hinder RA, Klingler P, Gadenstatter M, Perdikis G, Hinder PR. Reflux esophagitis in humans is a free radical event. Dis Esophagus 10:29-32, 1997.
31. Abdel-Mageed A, Agrawal KC. Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther 4:199-207, 1997.
32. Arora V, Iversen PL, Ebadi M. Manipulation of metallothionein expression in the regenerating rat liver using antisense oligonucleotides. Biochem Biophys Res Commun 246:711-718, 1998.
33. Apostolova MD, Cherian MG. Delay of M-phase onset by aphidicolin can retain the nuclear localization of zinc and metallothionein in 3T3L1 fibroblasts. J Cell Physiol 183:247-253, 2000.
34. Cherian MG, Apostolova MD. Nuclear localization of metallothionein during cell proliferation and differentiation. Cell Mol Biol 46:347-356, 2000.
35. Sato M, Bremner I. Oxygen free radicals and metallothionein. Free Radic Biol Med 14:325-337, 1993.
36. Cornell RP. Acute phase responses after acute liver injury by partial hepatectomy in rats as indicators of cytokine release. Hepatology 11:923-931, 1990.
37. Chen ML, Failla ML. Metallothionein metabolism in the liver and kidney of the streptozotocin-diabetic rat. Comp Biochem Physiol 90:439-445, 1988.
38. Molotkov A, Satoh M, Tohyama C. Induction of hepatic metallothioneins in tumor-bearing IL-6-null mice. Oncol Res 12:169-172, 2000.
39. Min KS, Mukai S, Ohta M, Onosaka S, Tanaka K. Glucocorticoid inhibition of inflammation-induced metallothionein synthesis in mouse liver. Toxicol Appl Pharmacol 113:293-298, 1992.